Search

Your search keyword '"Patton, Heather"' showing total 237 results
Start Over Author "Patton, Heather"
237 results on '"Patton, Heather"'

2. Early paracentesis is associated with better prognosis compared with late or no-paracentesis in hospitalized veterans with cirrhosis and ascites.

Author

Patel, Nilang, Silvey, Scott, OLeary, Jacqueline, Morgan, Timothy, Patton, Heather, Rogal, Shari, and Bajaj, Jasmohan

Subjects
Humans, Ascites, Veterans, Liver Transplantation, Liver Cirrhosis, Prognosis, Acute Kidney Injury
Abstract

Guidelines recommend that all hospitalized patients with cirrhosis and ascites receive an early (

Published
2023

4. Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease

Author

Tamaki, Nobuharu, Ahlholm, Noora, Luukkonen, Panu K, Porthan, Kimmo, Sharpton, Suzanne R, Ajmera, Veeral, Kono, Yuko, Dave, Shravan, Ahmed, Aijaz, Sundaram, Vinay, Wilkinson, Michael J, Patton, Heather, Gupta, Hersh, Cervantes, Vanessa, Hernandez, Christie, Lopez, Scarlett J, Loomba, Ria, Baumgartner, Amanda, Richards, Lisa, Arkkila, Perttu ET, Nemes, Katriina, Isoniemi, Helena, Yki-Järvinen, Hannele, and Loomba, Rohit

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Hepatitis, Digestive Diseases, Chronic Liver Disease and Cirrhosis, Liver Disease, Clinical Research, Good Health and Well Being, Humans, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, Prospective Studies, Elasticity Imaging Techniques, Liver Cirrhosis, Fibrosis, Epidemiology, Gastroenterology, Hepatology, Liver cancer, Medical and Health Sciences, Immunology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BACKGROUNDA pilot, single-center study showed that first-degree relatives of probands with nonalcoholic fatty liver disease (NAFLD) cirrhosis have a high risk of advanced fibrosis. We aimed to validate these findings using 2 independent cohorts from the US and Europe.METHODSThis prospective study included probands with NAFLD with advanced fibrosis, NAFLD without advanced fibrosis, and non-NAFLD, with at least 1 first-degree relative. A total of 396 first-degree relatives - 220 in a derivation cohort and 176 in a validation cohort - were enrolled in the study, and liver fibrosis was evaluated using magnetic resonance elastography and other noninvasive imaging modalities. The primary outcome was prevalence of advanced fibrosis in first-degree relatives.RESULTSPrevalence of advanced fibrosis in first-degree relatives of probands with NAFLD with advanced fibrosis, NAFLD without advanced fibrosis, and non-NAFLD was 15.6%, 5.9%, and 1.3%, respectively (P = 0.002), in the derivation cohort, and 14.0%, 2.6%, and 1.3%, respectively (P = 0.004), in the validation cohort. In multivariable-adjusted logistic regression models, age of ≥50 years (adjusted OR [aOR]: 2.63, 95% CI 1.0-6.7), male sex (aOR: 3.79, 95% CI 1.6-9.2), diabetes mellitus (aOR: 3.37, 95% CI 1.3-9), and a first-degree relative with NAFLD with advanced fibrosis (aOR: 11.8, 95% CI 2.5-57) were significant predictors of presence of advanced fibrosis (all P < 0.05).CONCLUSIONFirst-degree relatives of probands with NAFLD with advanced fibrosis have significantly increased risk of advanced fibrosis. Routine screening should be done in the first-degree relatives of patients with advanced fibrosis.FUNDINGSupported by NCATS (5UL1TR001442), NIDDK (U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318, P30DK120515, K23DK119460), NHLBI (P01HL147835), and NIAAA (U01AA029019); Academy of Finland grant 309263; the Novo Nordisk, EVO, and Sigrid Jusélius Foundations; and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 777377. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the EFPIA.

Published
2022

5. Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project

Author

Rogal, Shari S., Taddei, Tamar H., Monto, Alexander, Yakovchenko, Vera, Patton, Heather, Merante, Monica, Spoutz, Patrick, Chia, Linda, Yudkevich, Jennifer, Aytaman, Ayse, Rabiee, Atoosa, John, Binu V., Blechacz, Boris, Cai, Cindy X., Gilles, HoChong, Shah, Anand S., McCurdy, Heather, Puri, Puneet, Jou, Janice, Mazhar, Khurram, Dominitz, Jason A., Anwar, Jennifer, Morgan, Timothy R., and Ioannou, George N.

Published
2024
Full Text
View/download PDF

6. Expert opinion on bleeding risk from invasive procedures in cirrhosis

Author

Alix Riescher-Tuczkiewicz, Stephen H. Caldwell, Patrick S. Kamath, Erica Villa, Pierre-Emmanuel Rautou, Afdhal Nezam H, Ageno Walter, Bianchini Marcello, Blasi Annabel, Caldwell Stephen H, Callaway Mark, Cardenas Andres, Darwish Murad Sarwa, De Gottardi Andrea, De Pietri Lesley, De Raucourt Emmanuelle, Dell'Era Alessandra, Denys Alban, Elkrief Laure, Garcia-Pagan Juan-Carlos, Garcia-Tsao Guadalupe, Gatt Alexander, Giannini Edoardo G, Golfieri Rita, Greenberg Charles S, Hernández-Gea Virginia, Heydtmann Mathis, Intagliata Nicolas M, Kamath Patrick S, Lester Will, Magnusson Maria, Neuberger James, Northup Patrick G, O'Leary Jacqueline G, Patton Heather, Peck-Radosavljevic Markus, Pillai Anjana, Plessier Aurélie, Rautou Pierre-Emmanuel, Ripoll Cristina, Roberts Lara N, Sarwar Ammar, Senzolo Marco, Shukla Akash, Simioni Paolo, Simonetto Douglas A, Singal Ashwani K, Soto Robin, Stine Jonathan G, Tapper Elliot B, Thabut Dominique, Thachil Jecko, Tomescu Dana, Tripathi Dhiraj, Tsochatzis Emmanuel A, Villa Erica, and Valla Dominique

Subjects
haemorrhage, coagulation, haemostasis, biopsy, anticoagulant, procedural related bleeding, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background & Aims: Despite several recent international guidelines, no consensus exists on the bleeding risk nor haemostatic parameter thresholds that define the safety of invasive procedures in patients with cirrhosis. The aim of this study was to establish a position paper on the bleeding risk associated with invasive procedures in patients with cirrhosis among the experts involved in various guidelines. Methods: All experts involved in recent guidelines on the management of invasive procedures in patients with cirrhosis were invited to classify 80 procedures as ''high risk'' or ''low risk'' with respect to bleeding. Procedures were considered high risk when the estimated risk of major bleeding was 1.5% or more, or when even minor bleeding might lead to significant morbidity or death. The experts were also asked to choose safety thresholds for laboratory test values at which elective invasive procedures could be safely performed. The predetermined threshold considered as “consensus” was ≥75% agreement. Results: Fifty-two experts participated in the study. Out of 80 procedures, a consensus opinion was reached for 52 procedures (65%): 17 procedures were classified as “high risk”, primarily interventional endoscopic procedures, percutaneous organ biopsies, or procedures involving the central nervous system; and 35 as “low risk”, primarily “diagnostic” procedures. The lowest platelet counts at which performance of a low-risk procedure or a high-risk procedure/surgery were deemed acceptable were 30 × 109/L and 50 × 109/L, respectively. Experts did not believe that international normalised ratio should be considered before performing low-risk procedures; 71% also indicated that it should not be considered before performing high-risk procedures. Conclusions: This experience-based classification may be helpful to refine future study designs and to guide clinical decision making regarding invasive procedures in patients with cirrhosis. Impact and implications: Several risk classifications and management guidelines for invasive procedures in patients with cirrhosis have been proposed, but with conflicting recommendations. By providing a position paper, based on the opinion of a broad panel of experts, on the bleeding risk associated with 52 invasive procedures in patients with cirrhosis, this survey will help to provide a framework for future study design. The consensus on platelet count, international normalised ratio, fibrinogen and activated partial thromboplastin time identified in this survey will inform physicians regarding the laboratory test values considered acceptable by the experts prior to the performance of an elective invasive procedure in patients with cirrhosis.

Published
2024
Full Text
View/download PDF

7. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review

Author

Loomba, Rohit, Lim, Joseph K, Patton, Heather, and El-Serag, Hashem B

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Hepatitis, Rare Diseases, Liver Disease, Cancer, Prevention, Clinical Research, Liver Cancer, 4.1 Discovery and preclinical testing of markers and technologies, Good Health and Well Being, Carcinoma, Hepatocellular, Disease Progression, Early Detection of Cancer, Gastroenterology, Humans, Incidence, Liver Neoplasms, Mass Screening, Non-alcoholic Fatty Liver Disease, Practice Guidelines as Topic, Risk Factors, Societies, Medical, United States, Watchful Waiting, Cirrhosis, Fibrosis, HCC, NASH, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Nonalcoholic fatty liver disease (NAFLD) is a leading etiology for chronic liver disease with an immense public health impact and affects >25% of the US and global population. Up to 1 in 4 NAFLD patients may have nonalcoholic steatohepatitis (NASH). NASH is associated with significant morbidity and mortality due to complications of liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). Recent data confirm that HCC represents the fifth most common cancer and is the second leading cause of cancer-related death worldwide, and NAFLD has been identified as a rapidly emerging risk factor for this malignancy. NAFLD-associated liver complications are projected to become the leading indication for liver transplantation in the next decade. Despite evidence that NAFLD-associated HCC may arise in the absence of cirrhosis, is often diagnosed at advanced stages, and is associated with lower receipt of curative therapy and with poorer survival, current society guidelines provide limited guidance/recommendations addressing HCC surveillance in patients with NAFLD outside the context of established cirrhosis. Limited data are presently available to guide clinicians with respect to which patients with NAFLD should undergo HCC surveillance, optimal screening tools, frequency of monitoring, and the influence of coexisting host- and disease-related risk factors. Herein we present an evidence-based review addressing HCC risk in patients with NAFLD and provide Best Practice Advice statements to address key issues in clinical management.

Published
2020

8. Identification of Maltase Glucoamylase as a Biomarker of Acute Kidney Injury in Patients with Cirrhosis

Author

Awdishu, Linda, Tsunoda, Shirley, Pearlman, Michelle, Kokoy-Mondragon, Chanthel, Ghassemian, Majid, Naviaux, Robert K, Patton, Heather M, Mehta, Ravindra L, Vijay, Bhavya, and RamachandraRao, Satish P

Subjects
Prevention, Liver Disease, Clinical Research, Digestive Diseases, Kidney Disease, Chronic Liver Disease and Cirrhosis, Renal and urogenital, Good Health and Well Being
Abstract

BackgroundAcute kidney injury (AKI) is a frequent complication of decompensated cirrhosis with increased mortality. Traditional biomarkers such as serum creatinine are not sensitive for detecting injury without functional change. We hypothesize that urinary exosomes potentially carry markers that differentiate the type of kidney injury in cirrhotic patients.MethodsThis is a prospective, single-center, and observational study of adult patients with cirrhosis. The patient groups included healthy normal controls, compensated cirrhosis with normal kidney function, decompensated cirrhosis with normal kidney function, and decompensated cirrhosis with AKI. Data were extracted from the electronic health record including etiology of liver disease, MELD score, history of decompensation, Child-Turcotte-Pugh score, history of AKI, and medication exposures. Urine samples were collected at the time of consent. Urine exosome protein content was analyzed, and proteomic data were validated by immunoblotting. Statistical analysis included partial least squares-discriminant analysis coupled with variable importance in projection identification.ResultsEighteen cirrhotic subjects were enrolled, and six healthy control subjects were extracted from our biorepository. Urine exosomes were isolated, and 1572 proteins were identified. Maltase-glucoamylase was the top discriminating protein confirmed by western blotting.ConclusionsPatients with cirrhosis and AKI have upregulation of renal brush border disaccharidase, MGAM, in urinary exosomes which may differentiate the type of kidney injury in cirrhosis; however, the clinical significance of this requires further validation.

Published
2019

9. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Author

Gadano, Adrian, Martins, Marcelo, Angus, Peter, Bate, John, Danta, Mark, George, Jacob, Hodge, Alexander, Kontorinis, Nickolas, Roberts, Stuart, Sanagapalli, Santosh, Skoien, Richard, Thompson, Alexander, Zekry, Amany, Stauber, Rudolf, Trauner, Michael, Moreno, Christophe, Reynaert, Hendrik, Verbeke, Len, Silva, Mario Reis Alvares da, Parise, Edison, Oliveira, Claudia Pinto Marques Souza de, Araujo, Roberta Chaves, Martinelli, Ana de Lourdes Candolo, Borman, Meredith, Chandok, Natasha, Elkhashab, Magdy, Fraser, Hughie, Kaita, Kelly, Ma, Mang, Marotta, Paul, Ramji, Alnoor, Tam, Edward, Yoshida, Eric, Swain, Mark, Sebastiani, Giada, Petrunia, Denis, Abergel, Armando, Anty, Rodolphe, Bourlière, Marc, Boursier, Jérôme, Bureau, Christophe, Castera, Laurent, Habersetzer, François, Hézode, Christophe, Ledinghen, Victor De, Leroy, Vincent, Loustaud-Ratti, Véronique, Mathurin, Philippe, Pol, Stanislas, Zoulim, Fabien, Hinrichsen, Holger, Ingiliz, Patrick, Lammert, Frank, Manns, Michael, Schattenberg, Jörn, Schiefke, Ingolf, Trautwein, Christian, Zeuzem, Stefan, Hui, Aric, Li, King-Kong, Wong, Vincent, Acharya, Subrat, Chowdhury, Abhijit, Duseja, Ajay, Kapoor, Dharmesh, Mukewar, Shrikant, Sarin, Shiv, Shah, Samir, Shalimar, Sood, Ajit, Tantry, BV, Ben-Ari, Ziv, Katchman, Helena, Safadi, Rifaat, Veitsman, Ella, Zuckerman, Eli, Brunetto, Maurizia, Lampertico, Pietro, Mangia, Alessandra, Akahane, Takemi, Akuta, Norio, Eguchi, Yuichiro, Fujiyama, Shigetoshi, Genda, Takuya, Hiasa, Yoichi, Ido, Akio, Ikeda, Fusao, Ikegami, Tadashi, Imajo, Kento, Itoh, Yoshito, Iwasa, Motoh, Karino, Yoshiyasu, Kato, Naoya, Kawaguchi, Takumi, Kawanaka, Miwa, Kido, Masahiro, Kobayashi, Tomoo, Kurosaki, Masayuki, Matsuzaki, Yasushi, Mita, Eiji, Mizukoshi, Eishiro, Nakahara, Takashi, Nomura, Hideyuki, Notsumata, Kazuo, Okanoue, Takeshi, Saito, Satoshi, Sakugawa, Hiroshi, Suzuki, Yoshiyuki, Takaguchi, Koichi, Takaki, Akinobu, Takashima, Tomoyuki, Tanaka, Saiyu, Tsuji, Keiji, Ueno, Yoshiyuki, Umemura, Takeji, Uto, Hirofumi, Yamashita, Nobuyuki, Yanase, Mikio, Yatsuhashi, Hiroshi, Yoneda, Masashi, Chan, Wah Kheong, Tan, Soek Siam, Garza, Laura Cisneros, Ladron De Guevara Cetina, Alma, Angeles, Rocio Guadalupe Vargas, Silva, Francisca Martinez, Van Erpecum, Karel, Orr, David, Jabłkowski, Maciej, Jaroszewicz, Jerzy, Ramos, Jose, Ahmed, Taufique, Ang, Tiing, Dan, Yock young, Goh, Boon Bee, Kaliyaperumal, Kalaiyarasi, Yip, Cherng Hann, Baik, Soon Koo, Jang, Byoung Kuk, Jun, Dae Won, Kim, Won, Kim, Hyung Joon, Kim, Ji Hoon, Lee, Kwan Sik, Lee, Chun Kyon, Lim, Young-Suk, Park, Jun Yong, Tak, Won Young, Augustin, Salvador, Perez, Salvador Benlloch, Caballeria, Juan, Luis, Jose, Panero, Calleja, Rodríguez, Jose Carrión, Garcia, Javier Crespo, Samaniego, Javier Garcia, Gibert, Pere Ginès, Prieto, Martin, Gomez, Manuel Romero, Turnes, Juan, Dufour, Jean-Francois, Moriggia, Alberto, Sheen, I-Shyan, Kao, Jia-Horng, Cheng, Pin-Nan, Huang, Jee-Fu, Yang, Sheng-Shun, Su, Wei-Wen, Chen, Chi-Yi, Chien, Rong-Nan, Lo, Gin-Ho, Chu, Chi-Jen, Wang, Horng-Yuan, Hu, Jui-Ting, Huang, Yi Wen, Agarwal, Kosh, Allison, Michael, Anstee, Quentin, Austin, Andrew, Fowell, Andrew, Ch'ng, Chin Lye, Manousou, Pinelopi, Newsome, Philip, Ryder, Stephen, Shankar, Arun, Abdelmalek, Manal, Abrams, Gary, Aguilar, Humberto, Alam, Imtiaz, Alba, Laura, Alkhouri, Naim, Allen, Alina, Aqel, Bashar, Balart, Luis, Barritt, A. Sidney, IV, Behari, Jaideep, Bennett, Michael, Bernstein, David, Bhandari, Bal Raj, Bonacini, Maurizio, Borg, Brian, Brown, Kimberly, Bzowej, Natalie, Caldwell, Stephen, Chami, Tawfik, Coates, Allan, Cueli, Adolfo, Davis, Mitchell, deLemos, Andrew, Desai, Archita, Dunn, Winston, Ferreira, Nelson, Fine, Michael, Firpi-Morell, Roberto, Freedland, Curtis, Freilich, Bradley, Fuchs, Michael, Galambos, Michael, Gallegos-Orozco, Juan, Galler, Greg, Ghali, Maged, Ghalib, Reem, Gill, Satinder, Gillis, Marcum, Gilroy, Richard, Gordon, Stuart, Gunn, Nadege, Halegoua-DeMarzio, Dina, Hassan, Mohamed, Hassanein, Tarek, Herring, Robert, Jr., Hong, John, Huang, Jonathan, Kabler, Heidi, Kayali, Zeid, Knapple, Whitfield, Kolli, Geetha, Kowdley, Kris, Krause, Richard, Lawitz, Eric, Lidofsky, Steven, Lim, Joseph, Lipkis, Donald, Loomba, Rohit, Mahgoub, Amar, Malespin, Miguel, Manch, Richard, Mannis, Steven, Manos, Paul, McDonald, Thomas, McKenzie, Mark, Mena, Edward, Merriman, Raphael, Moehlen, Martin William, Montgomery, Richard, Murphy, Robert, Natarajan, Yamini, Neff, Guy, Noureddin, Mazen, Ortiz-Lasanta, Grisell, Pagadala, Mangesh, Patel, Keyur, Patton, Heather, Peyton, Adam, Pimstone, Neville, Poulos, John, Pound, David, Pyrsopoulos, Nikolaos, Rafiq, Nila, Ravendhran, Natarajan, Ravinuthala, Ravi, Reddy, K. Rajendar, Reindollar, Robert, Reynolds, Justin, Rinella, Mary, Rizvi, Syed, Rockey, Don, Rodriguez-Perez, Federico, Ruane, Peter, Rubin, Raymond, Ryan, Michael, Saeian, Kia, Sanyal, Arun, Sarkar, Souvik, Scanga, Andrew, Schiff, Eugene, Schmidt, Warren, Schneider, Jeffrey, Sepe, Thomas, Shah, Dhiren, Shaikh, Obaid, Shankar, Uday, Sheikh, Aasim, Sheikh, Muhammad, Sherman, Kenneth, Shiffman, Mitchell, Siddique, Asma, Smith, Matthew, Suarez, Rosa, Talal, Andrew, Te, Helen, Tekola, Bezawit, Tetri, Brent, Thuluvath, Paul, Toro, Doris, Torres, Dawn, Trinh, Huy, Trotter, James, Vento, Angel, Vierling, John, Vuppalanchi, Raj, Waters, Michael, Weisberg, Ilan, Wieland, Amanda, Williams, Alonzo, Younes, Ziad, Adams, Leon, Harding, Damian, Hodge, Alex, Kontorinis, Nick, Strasser, Simone, Thompson, Alex, Horsmans, Yves, Steenkiste, Christophe Van, Bailey, Robert, Giard, Jeanne-Marie, Montano-Loza, Aldo, Puglia, Marco, Tsoi, Keith, Larrey, Dominique, Nguyen-Khac, Eric, Ratziu, Vlad, Spengler, Ulrich, Wiegand, Johannes, Hui, Aric Josun, Acharya, Subrat Kumar, Sarin, Shiv Kumar, Tantry, Vishwanath, Braun, Marius, Hazzan, Rawi, Lurie, Yoav, Colombo, Massimo, Fujii, Hideki, Hashimoto, Etsuko, Kato, Masaki, Ogawa, Koji, Takehara, Tetsuo, Tokushige, Katsutoshi, Garza, Laura Esthela Cisneros, Ladrón De Guevara, Alma Laura, Schultz, Michael, Janczewska, Ewa, Toro, Doris H., Jeong, Sook-Hyang, Kim, Yoon Jun, Lee, Jin-Woo, Ang, Tiing Leong, Bee, George Goh Boon, Benlloch, Salvador, Caballería, Juan, Calleja, José Luis, Rodríguez, Jose A. Carrión, Crespo, Javier, Diago, Moises, Fernandez-Rodriguez, Conrado, García-Samaniego, Javier, Ginès, Pere, Romero, Manuel, Dufour, Jean-François, Alazawi, William, Ch'ng, Chin-Lye, Forton, Daniel, Priest, Matthew, Sheridan, David, Ankoma-Sey, Victor, Balakrishnan, Maya, Bambha, Kiran, Barritt, A. Sidney, Bhandari, Bal, Brandman, Danielle, Chang, Charissa, Corey, Kathleen, Feldman, Michael, Gholam, Pierre, Goff, John, Marzio, Dina Halegoua-De, Harrison, Stephen, Hellstern, Paul, Jr., Herring, Robert, Iyer, Rajalakshmi, Jakiche, Antoine, Kohli, Anita, Krok, Karen, Kugelmas, Marcelo, Kumar, Sonal, Lai, Michelle, Mahmoud, Mitchell, Mantry, Parvez, Marsano, Luis, Nguyen, Tuan, Park, James, Patton, Heather M., Pockros, Paul, Reddy, Rajender, Rodriguez, Miguel, Sarles, Harry, Satapathy, Sanjaya, Sedghi, Shahriar, Shah, Nikunj, Sheikh, Muhammad Yasin, Sigal, Samuel, Stanca, Carmen, Steinbook, Michael, Szabo, Gyongyi, Terrault, Norah, Tong, Myron, Victor, David, Zervos, Xaralambos, Harrison, Stephen A., Wong, Vincent Wai-Sun, Caldwell, Stephen H., Shiffman, Mitchell L., Camargo, Marianne, Li, Georgia, Kersey, Kathryn, Jia, Catherine, Zhu, Yanni, Djedjos, C. Stephen, Subramanian, G. Mani, Myers, Robert P., Anstee, Quentin M., Romero-Gomez, Manuel, Goodman, Zachary, Lawitz, Eric J., and Younossi, Zobair

Published
2020
Full Text
View/download PDF

10. Early detection of liver disease in patients with alcohol use disorder improves long-term abstinence.

Author

Orgill, Amelia, Jew, Michael H, Soltani, Maryam, Deioma, Ann, Grant, Meghan, Patton, Heather M, and Hsu, Cynthia L

Subjects
ALCOHOLISM treatment, REHABILITATION of people with alcoholism, COMPLICATIONS of alcoholism, RISK assessment, CIRRHOSIS of the liver, INTERPROFESSIONAL relations, MENTAL health services, DATA analysis, RESEARCH funding, SUBSTANCE abuse treatment, FISHER exact test, KRUSKAL-Wallis Test, MULTIPLE regression analysis, ALCOHOLIC liver diseases, TEMPERANCE, EVALUATION of medical care, RETROSPECTIVE studies, DESCRIPTIVE statistics, ULTRASONIC imaging, MULTIVARIATE analysis, DISEASE prevalence, LONGITUDINAL method, CHRONIC diseases, GASTROENTEROLOGISTS, ODDS ratio, VETERANS, MEDICAL records, ACQUISITION of data, CONVALESCENCE, STATISTICS, EARLY diagnosis, COMPARATIVE studies, TREATMENT programs, MEDICAL screening, ALCOHOL drinking, DATA analysis software, CONFIDENCE intervals, PULMONARY fibrosis, INTEGRATED health care delivery, PREVENTIVE health services, DISEASE risk factors
Abstract

Aims Excessive alcohol consumption is a major global health concern, contributing to millions of deaths annually and a significant proportion of cirrhosis cases; however, standardized protocols for early identification of alcohol-associated liver disease are lacking. In this retrospective cohort study, we aimed to understand the prevalence and risk factors associated with elevated liver stiffness measurement (LSM) in high-risk patients with alcohol use disorder (AUD) and identify variables associated with longitudinal abstinence and outcomes. Methods Veterans with severe AUD without known liver disease admitted to a 35-day residential substance use treatment program were offered liver health screening, including Fibroscan evaluation. Assessment of AUD severity and liver health outcomes were evaluated longitudinally by chart review. Results and Conclusions In a cohort of 257 veterans with severe AUD admitted to residential treatment, 185 underwent Fibroscan evaluation, and 22 were identified to have elevated LSM concerning for compensated advanced chronic liver disease. Patients with elevated LSM were more likely to remain abstinent after 1 year. About 41% of patients with LSM ≥ 10 kPa (5% of all screened patients) were confirmed to have cirrhosis on follow-up and incorporated into routine hepatology care. Screening of liver disease in high-risk populations with non-invasive imaging modalities provides an opportunity to identify patients at risk for compensated advanced chronic liver disease before decompensation. Identification of increased risk for advanced chronic liver disease may promote abstinence in patients with severe AUD. Collaboration between mental health professionals and hepatologists is critical for the integration of care for patients with AUD and liver disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis

Author

Yang, Ju Dong, Abdelmalek, Manal F, Guy, Cynthia D, Gill, Ryan M, Lavine, Joel E, Yates, Katherine, Klair, Jagpal, Terrault, Norah A, Clark, Jeanne M, Unalp-Arida, Aynur, Diehl, Anna Mae, Suzuki, Ayako, Dasarathy, Srinivasan, Dasarathy, Jaividhya, Hawkins, Carol, McCullough, Arthur J, Pagadala, Mangesh, Pai, Rish, Sargent, Ruth, Bashir, Mustafa, Buie, Stephanie, Guy, Cynthia, Kigongo, Christopher, Pan, Yi-Ping, Piercy, Dawn, Chalasani, Naga, Cummings, Oscar W, Gawrieh, Samer, Ghabril, Marwan, Marri, Smitha, Ragozzino, Linda, Sandrasegaran, Kumar, Vuppalanchi, Raj, King, Debra, Osmack, Pat, Siegner, Joan, Stewart, Susan, Neuschwander-Tetri, Brent A, Torretta, Susan, Ang, Brandon, Behling, Cynthia, Bhatt, Archana, Loomba, Rohit, Middleton, Michael, Patton, Heather, Sirlin, Claude, Aouizerat, Bradley, Bass, Nathan M, Brandman, Danielle, Ferrell, Linda D, Gill, Ryan, Hameed, Bilal, Ramos, Claudia, Terrault, Norah, Ungermann, Ashley, Atla, Pradeep, Croft, Brandon, Garcia, Rebekah, Garcia, Sonia, Sheikh, Muhammad, Singh, Mandeep, Boyett, Sherry, Carucci, Laura, Contos, Melissa J, Kraft, Kenneth, Luketic, Velimir AC, Puri, Puneet, Sanyal, Arun J, Schlosser, Jolene, Siddiqui, Mohhamad S, Wolford, Ben, Ackermann, Sarah, Cooney, Shannon, Coy, David, Gelinas, Katie, Kowdley, Kris V, Lee, Maximillian, Pierce, Tracey, Mooney, Jody, Nelson, James E, Shaw, Cheryl, Siddique, Asma, Wang, Chia, Brunt, Elizabeth M, Fowler, Kathryn, Kleiner, David E, Grave, Gilman D, Doo, Edward C, Hoofnagle, Jay H, Robuck, Patricia R, Sherker, Averell, Belt, Patricia, Donithan, Michele, Hallinan, Erin, and Isaacson, Milana

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Clinical Sciences, Digestive Diseases, Liver Disease, Contraception/Reproduction, Prevention, Hepatitis, Estrogen, Chronic Liver Disease and Cirrhosis, Aging, Good Health and Well Being, Adolescent, Adult, Aged, Cross-Sectional Studies, Female, Histocytochemistry, Hormones, Humans, Male, Menopause, Middle Aged, Non-alcoholic Fatty Liver Disease, Reproduction, Risk Factors, Sex Factors, United States, Young Adult, Gender Differences, Fibrosis, Risk Factor Analysis., Nonalcoholic Steatohepatitis Clinical Research Network, Risk Factor Analysis, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background & aimsSex and sex hormones can affect responses of patients with nonalcoholic fatty liver disease (NAFLD) to metabolic stress and development of hepatocyte injury and inflammation.MethodsWe collected data from 3 large U.S. studies of patients with NAFLD (between October 2004 and June 2013) to assess the association between histologic severity and sex, menopause status, synthetic hormone use, and menstrual abnormalities in 1112 patients with a histologic diagnosis of NAFLD. We performed logistic or ordinal logistic regression models, adjusting for covariates relevant to an increase of hepatic metabolic stress.ResultsPremenopausal women were at an increased risk of lobular inflammation, hepatocyte ballooning, and Mallory-Denk bodies than men and also at an increased risk of lobular inflammation and Mallory-Denk bodies than postmenopausal women (P < .01). Use of oral contraceptives was associated with an increased risk of lobular inflammation and Mallory-Denk bodies in premenopausal women, whereas hormone replacement therapy was associated with an increased risk of lobular inflammation in postmenopausal women (P < .05).ConclusionsBeing a premenopausal woman or a female user of synthetic hormones is associated with increased histologic severity of hepatocyte injury and inflammation among patients with NAFLD at given levels of hepatic metabolic stress.

Published
2017

15. Statistical Software Use in Canadian University Courses: Current Trends and Future Directions

Author

Davidson, Heather, Jabbari, Yasaman, Patton, Heather, O'Hagan, Fergal, Peters, Kevin, and Cribbie, Robert

Abstract

Two controversial topics related to the teaching of statistics to psychology students are (a) when to introduce statistical software and (b) which statistical software package to use. The current research looked at the use of statistical software in statistics classes from every university with a psychology program in Canada. Researchers collected data from 321 statistics courses offered to psychology students at 65 Canadian universities and coded the type of statistical software used (if any) in each course. Results show that slightly more than half of all universities introduce software at the introductory level. Point-and-click software is most popular, particularly SPSS. There is a considerable amount of variability in when and which software is introduced to students. Departments can use these data to inform their own practices.

Published
2019
Full Text
View/download PDF

17. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial

Author

Le, Thuy‐Anh, Chen, Joshua, Changchien, Christopher, Peterson, Michael R, Kono, Yuko, Patton, Heather, Cohen, Benjamin L, Brenner, David, Sirlin, Claude, Loomba, Rohit, and Consortium, for the San Diego Integrated NAFLD Research

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Chronic Liver Disease and Cirrhosis, Clinical Research, Liver Disease, Digestive Diseases, Hepatitis, Biomedical Imaging, 4.1 Discovery and preclinical testing of markers and technologies, Oral and gastrointestinal, Allylamine, Anticholesteremic Agents, Colesevelam Hydrochloride, Double-Blind Method, Fatty Liver, Female, Humans, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, Prospective Studies, San Diego Integrated NAFLD Research Consortium, Medical Biochemistry and Metabolomics, Immunology, Gastroenterology & Hepatology, Clinical sciences
Abstract

UnlabelledBile acid sequestrants (BAS) lower plasma low density lipoprotein levels and improve glycemic control. Colestimide, a BAS, has been claimed by computed tomography to reduce liver fat. Therefore, we examined the efficacy of colesevelam, a potent BAS, to decrease liver fat in patients with biopsy-proven nonalcoholic steatohepatitis (NASH). Liver fat was measured by a novel magnetic resonance imaging (MRI) technique, the proton-density-fat-fraction (PDFF), as well as by conventional MR spectroscopy (MRS). Fifty patients with biopsy-proven NASH were randomly assigned to either colesevelam 3.75 g/day orally or placebo for 24 weeks. The primary outcome was change in liver fat as measured by MRI-PDFF in colocalized regions of interest within each of the nine liver segments. Compared with placebo, colesevelam increased liver fat by MRI-PDFF in all nine segments of the liver with a mean difference of 5.6% (P = 0.002). We cross-validated the MRI-PDFF-determined fat content with that assessed by colocalized MRS; the latter showed a mean difference of 4.9% (P = 0.014) in liver fat between the colesevelam and the placebo arms. MRI-PDFF correlated strongly with MRS-determined hepatic fat content (r(2) = 0.96, P < 0.0001). Liver biopsy assessment of steatosis, cellular injury, and lobular inflammation did not detect any effect of treatment.ConclusionColesevelam increases liver fat in patients with NASH as assessed by MRI as well as MRS without significant changes seen on histology. Thus, MRI and MRS may be better than histology to detect longitudinal changes in hepatic fat in NASH. Underlying mechanisms and whether the small MR-detected increase in liver fat has clinical consequences is not known.

Published
2012

18. Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project

Author

Rogal, Shari S., primary, Taddei, Tamar, additional, Monto, Alexander, additional, Yakovchenko, Vera, additional, Patton, Heather, additional, Merante, Monica, additional, Spoutz, Patrick, additional, Chia, Linda, additional, Yudkevich, Jennifer, additional, Aytaman, Ayse, additional, Rabiee, Atoosa, additional, John, Binu, additional, Blechacz, Boris, additional, Cai, Cindy X., additional, Gilles, Hochong, additional, Shah, Anand S., additional, McCurdy, Heather, additional, Puri, Puneet, additional, Jou, Janice, additional, Mazhar, Khurram, additional, Dominitz, Jason, additional, Anwar, Jennifer, additional, Morgan, Timothy R., additional, and Ioannou, George N., additional

Published
2023
Full Text
View/download PDF

19. Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis

Author

Dasarathy, Srinivasan, Dasarathy, Jaividhya, Hawkins, Carol, McCullough, Arthur J., Pagadala, Mangesh, Pai, Rish, Sargent, Ruth, Abdelmalek, Manal F., Bashir, Mustafa, Buie, Stephanie, Diehl, Anna Mae, Guy, Cynthia, Kigongo, Christopher, Pan, Yi-Ping, Piercy, Dawn, Chalasani, Naga, Cummings, Oscar W., Gawrieh, Samer, Ghabril, Marwan, Marri, Smitha, Ragozzino, Linda, Sandrasegaran, Kumar, Vuppalanchi, Raj, King, Debra, Osmack, Pat, Siegner, Joan, Stewart, Susan, Neuschwander-Tetri, Brent A., Torretta, Susan, Ang, Brandon, Behling, Cynthia, Bhatt, Archana, Loomba, Rohit, Middleton, Michael, Patton, Heather, Sirlin, Claude, Aouizerat, Bradley, Bass, Nathan M., Brandman, Danielle, Ferrell, Linda D., Gill, Ryan, Hameed, Bilal, Ramos, Claudia, Terrault, Norah, Ungermann, Ashley, Atla, Pradeep, Croft, Brandon, Garcia, Rebekah, Garcia, Sonia, Sheikh, Muhammad, Singh, Mandeep, Boyett, Sherry, Carucci, Laura, Contos, Melissa J., Kraft, Kenneth, Luketic, Velimir A.C., Puri, Puneet, Sanyal, Arun J., Schlosser, Jolene, Siddiqui, Mohhamad S., Wolford, Ben, Ackermann, Sarah, Cooney, Shannon, Coy, David, Gelinas, Katie, Kowdley, Kris V., Lee, Maximillian, Pierce, Tracey, Mooney, Jody, Nelson, James E., Shaw, Cheryl, Siddique, Asma, Wang, Chia, Brunt, Elizabeth M., Fowler, Kathryn, Kleiner, David E., Grave, Gilman D., Doo, Edward C., Hoofnagle, Jay H., Robuck, Patricia R., Sherker, Averell, Belt, Patricia, Clark, Jeanne M., Donithan, Michele, Hallinan, Erin, Isaacson, Milana, May, Kevin P., Miriel, Laura, Sternberg, Alice, Tonascia, James, Ünalp-Arida, Aynur, Van Natta, Mark, Vaughn, Ivana, Wilson, Laura, Yates, Katherine, Yang, Ju Dong, Guy, Cynthia D., Gill, Ryan M., Lavine, Joel E., Klair, Jagpal, Terrault, Norah A., Unalp-Arida, Aynur, and Suzuki, Ayako

Published
2017
Full Text
View/download PDF

21. Primary prophylaxis for spontaneous bacterial peritonitis is linked to antibiotic resistance in the Veterans Health Administration

Author

Badal, Bryan D., primary, Silvey, Scott, additional, Dragilev, Lyuba, additional, O’Leary, Jacqueline G., additional, Morgan, Timothy R., additional, Cheung, Ramsey, additional, Patel, Arpan, additional, Rogal, Shari, additional, Patton, Heather, additional, Nobbe, Anna, additional, Jakab, Sofia S., additional, Liu, Jinze, additional, Patel, Nilang, additional, and Bajaj, Jasmohan S., additional

Published
2023
Full Text
View/download PDF

24. Risk of advanced fibrosis in first-degree relatives of with nonalcoholic liver disease

Author

Tamaki, Nobuharu, Ahlholm, Noora, Luukkonen, Panu K., Porthan, Kimmo, Sharpton, Suzanne R., Ajmera, Veeral, Kono, Yuko, Dave, Shravan, Ahmed, Aijaz, Sundaram, Vinay, Wilkinson, Michael J., Patton, Heather, Gupta, Hersh, Cervantes, Vanessa, Hernandez, Christie, Lopez, Scarlett J., Loomba, Ria, Baumgartner, Amanda, Richards, Lisa, Arkkila, Perttu E. T., Nemes, Katriina, Isoniemi, Helena, Yki-Järvinen, Hannele, Loomba, Rohit, Clinicum, University of Helsinki, HUS Internal Medicine and Rehabilitation, Department of Medicine, Kardiologian yksikkö, HUS Abdominal Center, Gastroenterologian yksikkö, IV kirurgian klinikka, and Helsinki University Hospital Area

Subjects
Steatosis, 3121 General medicine, internal medicine and other clinical medicine
Published
2022

26. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial

Author

Thompson, Julie, Jones, Natasha, Al‐Khafaji, Ali, Malik, Shahid, Reich, David, Munoz, Santiago, MacNicholas, Ross, Hassanein, Tarek, Teperman, Lewis, Stein, Lance, Duarte‐Rojo, Andrés, Malik, Raza, Adhami, Talal, Asrani, Sumeet, Shah, Nikunj, Gaglio, Paul, Duddempudi, Anupama, Borg, Brian, Jalan, Rajiv, Brown, Robert, Patton, Heather, Satoskar, Rohit, Rossi, Simona, Parikh, Amay, ElSharkawy, Ahmed, Mantry, Parvez, Sher, Linda, Wolf, David, Hart, Marquis, Landis, Charles, Wigg, Alan, Habib, Shahid, McCaughan, Geoffrey, Colquhoun, Steven, Henry, Alyssa, Bedard, Patricia, Landeen, Lee, Millis, Michael, Ashley, Robert, Frank, William, Henry, Andrew, Stange, Jan, and Subramanian, Ram

Published
2018
Full Text
View/download PDF

31. Reply

Author

Henry, Zachary, primary and Patton, Heather, additional

Published
2022
Full Text
View/download PDF

41. Additional file 1 of Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT

Author

Patton, Heather, Burchette, Raoul, Tovar, Stephanie, Pio, Jose, Jiaxiao Shi, and Nyberg, Lisa M.

Abstract

Additional file 1. Comprehensive list of ICD9 and ICD 10 Codes used to identify atherosclerotic cardiovascular disease in study population as a comorbid health condition.

Published
2020
Full Text
View/download PDF

42. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.

Author

Lim, Joseph, Lim, Joseph, Patton, Heather, El-Serag, Hashem, Loomba, Rohit, Lim, Joseph, Lim, Joseph, Patton, Heather, El-Serag, Hashem, and Loomba, Rohit

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a leading etiology for chronic liver disease with an immense public health impact and affects >25% of the US and global population. Up to 1 in 4 NAFLD patients may have nonalcoholic steatohepatitis (NASH). NASH is associated with significant morbidity and mortality due to complications of liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). Recent data confirm that HCC represents the fifth most common cancer and is the second leading cause of cancer-related death worldwide, and NAFLD has been identified as a rapidly emerging risk factor for this malignancy. NAFLD-associated liver complications are projected to become the leading indication for liver transplantation in the next decade. Despite evidence that NAFLD-associated HCC may arise in the absence of cirrhosis, is often diagnosed at advanced stages, and is associated with lower receipt of curative therapy and with poorer survival, current society guidelines provide limited guidance/recommendations addressing HCC surveillance in patients with NAFLD outside the context of established cirrhosis. Limited data are presently available to guide clinicians with respect to which patients with NAFLD should undergo HCC surveillance, optimal screening tools, frequency of monitoring, and the influence of coexisting host- and disease-related risk factors. Herein we present an evidence-based review addressing HCC risk in patients with NAFLD and provide Best Practice Advice statements to address key issues in clinical management.

Published
2020

45. Contributors

Author

Adams, Paul C., primary, Albrecht, Helmut, additional, Bajaj, Jasmohan, additional, Baik, Soon Koo, additional, Beuers, Ulrich, additional, Biggins, Scott W., additional, Bismuth, Henri, additional, Boberg, Kirsten Muri, additional, Bonkovsky, Herbert L., additional, Bosch, Jaime, additional, Boyer, Thomas D., additional, Brunt, Elizabeth M., additional, Caselitz, Martin, additional, Caselmann, Wolfgang H., additional, Cave, Matt, additional, Chan, Henry Lik-Yuen, additional, Chang, Kyong-Mi, additional, Ciancio, Alessia, additional, Colombo, Massimo, additional, Conjeevaram, Hari S., additional, Cox, Diane W., additional, Day, Chris P., additional, Doctor, R. Brian, additional, Oude Elferink, Ronald P.J., additional, Elisofon, Scott A., additional, El-Serag, Hashem B., additional, Esmat, Gamal, additional, Everson, Gregory T., additional, Falkner, Keith Cameron, additional, Fallon, Michael B., additional, Feng, Sandy, additional, Fischer, Hans-Peter, additional, Fortune, Brett E., additional, Friedman, Scott L., additional, García-Pagán, J.C., additional, Garcia-Tsao, Guadalupe, additional, Ghishan, Fayez K., additional, Gores, Gregory J., additional, Gruessner, Rainer W., additional, Gupta, Sanjeev, additional, Hammoud, Ghassan M., additional, Heathcote, E.J., additional, Helmke, Steve M., additional, Hirschfield, G.M., additional, Hunt, Douglas, additional, Iavarone, Massimo, additional, Ibdah, Jamal A., additional, Imbert-Bismut, Françoise, additional, Jansen, Peter L.M., additional, Johnson, Benjamin F., additional, F. Jonas, Maureen M., additional, Jones, Dean P., additional, Kamath, Patrick S., additional, Karlsen, Tom H., additional, Kelly, Deirdre, additional, Kettelle, J., additional, Khan, Khalid M., additional, Knolle, Percy, additional, Kramer, David J., additional, Kumar, Manoj, additional, Kumar, Navaneeth C., additional, Lai, Jennifer C., additional, Lapointe, Réal, additional, Lazaridis, Konstantinos N., additional, Lechel, André, additional, Lee, Samuel S., additional, Lencioni, Riccardo, additional, Levy, Cynthia, additional, Lindor, Keith D., additional, Locarnini, Stephen, additional, Lok, Anna S.F., additional, Malhi, Harmeet, additional, Manns, Michael P., additional, Marrero, Jorge A., additional, McClain, Craig, additional, McCuskey, Robert, additional, McGovern, Barbara H., additional, McHutchison, John G., additional, Moradpour, Darius, additional, Navarro, Victor J., additional, Neuberger, James, additional, Nevah R., Moises I., additional, Nevzorova, Yulia A., additional, Patton, Heather M., additional, Penin, François, additional, Perlmutter, David, additional, Plessier, Aurélie, additional, Poynard, Thierry, additional, Puri, Puneet, additional, Rice, Charles, additional, Rizzetto, Mario, additional, Roberts, Eve A., additional, Rockey, Don C., additional, Roy-Chowdhury, Jayanta, additional, Roy-Chowdhury, Namita, additional, Rudolph, K. Lenhard, additional, Russo, Mark W., additional, Saab, Sammy, additional, Sanyal, Arun J., additional, Sarin, S.K., additional, Schrumpf, Erik, additional, Seeff, Leonard B., additional, Seijo, S., additional, Shah, Vijay H., additional, Shedlofsky, Steven I., additional, Shouval, Daniel, additional, Sirlin, Claude B., additional, Smith, Maxwell L., additional, Smorodinsky, Emmanuil, additional, Spengler, Ulrich, additional, Sterling, Richard K., additional, Stewart, Stephen F., additional, Strader, Doris B., additional, Strassburg, Christian P., additional, Stravitz, R. Todd, additional, Sud, Priti, additional, Sulkowski, Mark S., additional, Talwalkar, Jayant A., additional, Terrault, Norah A., additional, Tillmann, Hans L., additional, Trautwein, Christian, additional, Vagefi, Parsia A., additional, Valla, Dominique, additional, Wagner, Siegfried, additional, Warner, Nadia, additional, Wong, Vincent Wai-Sun, additional, and Zayed, Naglaa, additional

Published
2012
Full Text
View/download PDF

47. Fatty Liver Disease

Author

Mazhar, Sameer M., primary, Patton, Heather M., additional, Scuderi, Richard T., additional, Yokoo, Takeshi, additional, Faria, Silvana C., additional, and Sirlin, Claude B., additional

Published
2011
Full Text
View/download PDF

48. Contributors

Author

Agarwal, Abhishek Rajendra, primary, Aguirre, Diego A., additional, Aher, Pritish, additional, Anderson, Stephan W., additional, Asrani, Ashwin, additional, Banerjee, Arpan K., additional, Bennett, William, additional, Berggruen, Senta, additional, Blake, Michael, additional, Brancatelli, Giuseppe, additional, Cai, Wenli, additional, Cantisani, Vito, additional, Carbognin, Giovanni, additional, Catalano, Onofrio, additional, Chew, Michael, additional, Chowdhry, Aqeel Ahmad, additional, Choy, Garry, additional, Colen, Rivka R., additional, Cronin, Carmel, additional, Dachman, Abraham H., additional, D’Ambrosio, Ugo, additional, Desai, Hemali, additional, D’Onofrio, Mirko, additional, Faria, Silvana C., additional, Fibus, Todd, additional, Flores, Efrén J., additional, Frank, Mark, additional, Galluzzo, Anna, additional, Ganesan, Karthik, additional, Garg, Alpa G., additional, Gasparaitis, Arunas E., additional, Gee, Michael S., additional, Ghosh, Sukanya, additional, Grant, Thomas, additional, Graziani, Rossella, additional, Gulati, Kavita, additional, Gupta, Arti, additional, Hahn, Peter F., additional, Hammond, Nancy A., additional, Hanna, Robert, additional, Harri, Peter A., additional, Harris, Gordon J., additional, Hawes, Donald, additional, Pampaloni, Miguel Hernandez, additional, Ho, Mai-Lan, additional, Holalkere, Nagaraj-Setty, additional, Jambhekar, Kedar, additional, Jankharia, Bijal, additional, Jha, Saurabh, additional, Joshi, Akash, additional, Kalva, Sanjeeva P., additional, R., Avinash Kambadakone, additional, Katz, David P., additional, Kesavarapu, Keerthana, additional, Kim, Danny, additional, Kim, Kyoung Won, additional, Kim, Min Ju, additional, Koch, Marie R., additional, Kulkarni, Kirti, additional, Kulkarni, Naveen M., additional, Kurup, A. Nick, additional, Lala, Somesh, additional, Lall, Chandana G., additional, Lenhart, Dipti K., additional, Liu, Bob, additional, Ma, Xiaozhou, additional, Macari, Michael, additional, Manfredi, Riccardo, additional, Marcantonio, Andrea, additional, Marin, Daniele, additional, Martinez, Jaime, additional, Masrani, Deepa, additional, Mazhar, Sameer M., additional, Mazumdar, Vishakha, additional, McDowell, Jennifer, additional, Mittal, Pardeep, additional, Moore, Michael, additional, Morana, Giovanni, additional, Morani, Ajaykumar, additional, Motton, Massimiliano, additional, Narin, Ozden, additional, Narra, Vamsidhar R., additional, Nikolaidis, Paul, additional, Oto, Aytekin, additional, Pandey, Tarun, additional, Panek, Ralph C., additional, Patton, Heather M., additional, Johnston, Rocio Perez, additional, Perini, Rodolfo F., additional, Peterson, Christine M., additional, Peterson, Michael R., additional, Petralia, Giuseppe, additional, Power, Niall, additional, Prabhakar, Anand M., additional, Prabhakar, Hima B., additional, Prabhakar, Priya D., additional, Prasad, Srinivasa R., additional, Pryma, Daniel A., additional, Rajesh, Arumugam, additional, Rebello, Anuradha S., additional, Rezvani, Maryam, additional, Rivero, Oscar M., additional, Roedl, Johannes B., additional, Rosman, David A., additional, Sahani, Dushyant V., additional, Sainani, Nisha I., additional, Samir, Anthony E., additional, Sandrasegaran, Kumaresan, additional, Santillan, Cynthia S., additional, Sanyal, Rupan, additional, Saunders, Alissa, additional, Scuderi, Richard T., additional, Seale, Melanie, additional, Sebastian, Sunit, additional, Shah, Hemendra, additional, Shah, Shetal N., additional, Shah, Zarine K., additional, Shiehmorteza, Masoud, additional, Singh, Ajay, additional, Singh, Anand, additional, Sirlin, Claude B., additional, Small, William, additional, Soto, Jorge A., additional, Stein, Lance L., additional, Surabhi, Venkateswar R., additional, Taouli, Bachir, additional, Testoni, Marco, additional, Thabet, Ashraf, additional, Tomei, Ernesto, additional, Udeshi, Michelle, additional, Uppot, Raul N., additional, Vaidya, Sujit, additional, Viswamitra, Sanjaya, additional, Walker, T. Gregory, additional, Westra, Sjirk J., additional, Yaghmai, Vahid, additional, Yokoo, Takeshi, additional, and Yoshida, Hiroyuki, additional

Published
2011
Full Text
View/download PDF

49. Hepatic Iron Overload

Author

Patton, Heather M., primary, Mazhar, Sameer M., additional, Peterson, Michael R., additional, Hanna, Robert, additional, Ganesan, Karthik, additional, and Sirlin, Claude B., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results